ARCHIVES

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

This article is from The Cancer Letter archive.

Vol. 36 No. 8 | August 30, 2013

Download PDF Visit The Full Archive

Related Articles

Nature Editorial Criticizes NCI PR Spending

March 15, 2013

ODAC Recommends Approval Of Nplate For Thrombocytopenia.

March 21, 2008

IOM To Advise Army On Spending $210 Mil. Breast Cancer Money

January 8, 1993

Low-Dose Warfarin Prevents Blood Clots, NIH Study Finds

February 28, 2003

Agency Expands Gleevec Label To Include Rare GIST Subset

February 24, 2012

New Subcontracts Planned In Bioassay Program Run by Traco-JITCO

May 23, 1975